Viking Therapeutics, Inc. 0VQA.L
0VQA.L
Viking Therapeutics, Inc. 0Y5E.L
Perrigo Company plc 0SZI.L
Corbus Pharmaceuticals Holdings, Inc. 0HKF.L
Axsome Therapeutics, Inc. 0T6G.L
Q32 Bio Inc. 0HF9.L
Amicus Therapeutics, Inc. 0VGI.L
TG Therapeutics, Inc. 0EE0.L
uniQure N.V. 0KF3.L
Palatin Technologies, Inc. 0HB0.L
Agios Pharmaceuticals, Inc.
Viking Therapeutics, Inc. 0Y5E.L
Perrigo Company plc 0SZI.L
Corbus Pharmaceuticals Holdings, Inc. 0HKF.L
Axsome Therapeutics, Inc. 0T6G.L
Q32 Bio Inc. 0HF9.L
Amicus Therapeutics, Inc. 0VGI.L
TG Therapeutics, Inc. 0EE0.L
uniQure N.V. 0KF3.L
Palatin Technologies, Inc. 0HB0.L
Agios Pharmaceuticals, Inc.
Performance
| Periode | 0VQA.L | 0Y5E.L | 0SZI.L | 0HKF.L | 0T6G.L | 0HF9.L | 0VGI.L | 0EE0.L | 0KF3.L | 0HB0.L |
|---|---|---|---|---|---|---|---|---|---|---|
| 6M | 52.09 % | -11.88 % | 180.45 % | 23.36 % | 94.01 % | 28.01 % | 32.21 % | 604.70 % | -29.19 % | 56.92 % |
| YTD | -19.02 % | -18.57 % | 34.08 % | 34.43 % | 11.10 % | -13.07 % | 19.60 % | 246.92 % | -85.98 % | 21.24 % |
| 1Y | -49.64 % | -11.48 % | -14.59 % | 40.86 % | -91.84 % | -21.12 % | 64.65 % | 1 024.25 % | -81.36 % | -2.66 % |
| 3Y | 916.67 % | -35.84 % | 337.52 % | 162.26 % | -85.36 % | -25.30 % | 589.78 % | 229.87 % | -96.86 % | 42.73 % |
| 5Y | 433.39 % | -35.84 % | -48.54 % | 3 486.27 % | -98.03 % | -14.26 % | 207.56 % | 70.97 % | -99.07 % | 18.79 % |
| 10Y | 127.30 % | -35.84 % | -91.41 % | 3 486.27 % | -99.02 % | -14.26 % | 207.56 % | 225.27 % | -99.27 % | -49.73 % |
| From the beginning | 127.30 % | -35.84 % | -91.41 % | 3 486.27 % | -99.02 % | -14.26 % | 207.56 % | 225.27 % | -99.27 % | -49.73 % |